| [1] |
Becker K,Mueller JD,Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J]. Cancer, 2003, 98(7): 1521-1530.
|
| [2] |
Dworak O,Keilholz L and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy[J]. Int J Colorectal Dis, 1997, 12(1): 19-23.
|
| [3] |
Mandard AM,Dalibard F,Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations[J]. Cancer, 1994, 73(11): 2680-2686.
|
| [4] |
Rodel C,Martus P,Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2005, 23(34): 8688-8696.
|
| [5] |
Wheeler JM,Warren BF,Mortensen NJ, et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system[J]. Diseases of the colon and rectum, 2002, 45(8): 1051-1056.
|
| [6] |
Quah HM,Chou JF,Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation[J]. Cancer, 2008, 113(1): 57-64.
|
| [7] |
Zhang LN,Xiao WW,Xi SY, et al. Pathological Assessment of the AJCC Tumor Regression Grading System After Preoperative Chemoradiotherapy for Chinese Locally Advanced Rectal Cancer[J]. Medicine, 2016, 95(3): e2272.
|
| [8] |
Wheeler JM,Dodds E,Warren BF, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade[J]. Diseases of the colon and rectum, 2004, 47(12): 2025-2031.
|
| [9] |
Pucciarelli S,Toppan P,Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome[J]. Diseases of the colon and rectum, 2004, 47(11): 1798-1807.
|
| [10] |
Maas M,Nelemans PJ,Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. The Lancet Oncology, 2010, 11(9): 835-844.
|
| [11] |
Patel UB,Taylor F,Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2011, 29(28): 3753-3760.
|
| [12] |
Pucciarelli S,De Paoli A,Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial[J]. Diseases of the colon and rectum, 2013, 56(12): 1349-1356.
|
| [13] |
Habr-Gama A,Sabbaga J,Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?[J]. Diseases of the colon and rectum, 2013, 56(10): 1109-1117.
|
| [14] |
Maas M,Beets-Tan RG,Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2011, 29(35): 4633-4640.
|
| [15] |
Bosset JF,Collette L,Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J]. The New England journal of medicine, 2006, 355(11): 1114-1123.
|
| [16] |
Kockerling F,Raymond MA,Altendorf-Hofmann A, et al. Influence of surgery on metachronous distant metastases and survival in rectal cancer[J]. Journal Of Clinical Oncology, 1998, 16(1): 324-329.
|
| [17] |
Glynne-Jones R,Mawdsley S,Pearce T, et al. Alternative clinical end points in rectal cancer--are we getting closer?[J]. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2006, 17(8): 1239-1248.
|
| [18] |
De Gruttola VG,Clax P,DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop[J]. Controlled Clinical Trials, 2001, 22(5): 485-502.
|
| [19] |
Buyse M and Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments[J]. Biometrics, 1998, 54(3): 1014-1029.
|
| [20] |
Bosset JF,Calais G,Mineur L, et al. Preoperative radiation (Preop RT) in rectal cancer: Effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial[J]. Journal Of Clinical Oncology, 2005, 23(16): 247S-247S.
|
| [21] |
Conroy T,Bonnetain F,Chapet O, et al. Preoperative (preop) radiotherapy (RT)+5FU/folinic acid (FA) in T3, 4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial[J]. Journal Of Clinical Oncology, 2004, 22(14): 276S-276S.
|
| [22] |
Sauer R,Becker H,Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. New England Journal Of Medicine, 2004, 351(17): 1731-1740.
|
| [23] |
Gerard J,Bonnetain F,Conroy T, et al. Preoperative concurrent chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers. Results of the FFCD 9203 randomized trial[J]. Ejc Supplements, 2005, 3(2): 170.
|
| [24] |
Bosset J-F,Collette L,Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J]. New England Journal Of Medicine, 2006, 355(11): 1114-1123.
|
| [25] |
Sargent DJ,Patiyil S,Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20, 898 patients enrolled onto 18 randomized trials from the ACCENT Group[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, 25(29): 4569-4574.
|
| [26] |
Guillem JG,Chessin DB,Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer[J]. Annals of surgery, 2005, 241(5): 829-836; discussion 836-828.
|